Extended-spectrum beta-lactamases (ESBL) and AmpC producing-Escherichia coli have spread worldwide, but data about ESBL-producing-E. coli in the Northern and Eastern regions of Europe is scant. The aim of this study has been to describe the phenotypical and molecular epidemiology of different ESBL/AmpC/Carbapenemases genes in E. coli strains isolated from the Baltic States (Estonia, Latvia, and Lithuania), Norway and St. Petersburg (Russia), and to determine the predominant multilocus sequence type and single nucleotide polymorphisms diversity of E. coli isolates deduced by whole genome sequencing (WGS). A total of 10,780 clinical E. coli strains were screened for reduced sensitivity to third-generation cephalosporins. They were collected from 21 hospitals located in Estonia, Latvia, Lithuania, Norway and St. Petersburg during a 5 month period in 2012. The overall prevalence of ESBL/AmpC strains was 4.7% by phenotypical test and 3.9% by sequencing. We found more strains with the ESBL/AmpC phenotype and genotype in St. Petersburg and Latvia than other countries. Of phenotypic E. coli strains, 85% contained confirmed ESBL genes (including bla CTX−M , bla TEM−29 , bla TEM−71 ), AmpC genes (bla CMY−59 , bla ACT−12/−15/−20 , bla ESC−6 , bla FEC−1 , bla DHA−1 ), or carbapenemase genes (bla NDM−1 ). bla CTX−M−1 , bla CTX−M−14 and bla CTX−M−15 were found in all countries, but bla CTX−M−15 prevalence was higher in Latvia than in St. Petersburg (Russia), Estonia, Norway and Lithuania. The dominating AmpC genes were bla CMY−59 in the Baltic States and Norway, and bla DHA−1 in St. Petersburg. E. coli strains belonged Frontiers in Microbiology | www.frontiersin.org 1 November 2019 | Volume 10 | Article 2465 Sepp et al.
INTRODUCTION
Antimicrobial resistance is an emerging problem worldwide. Each year, 33,000 people die from an infection due to bacterial resistance to antibiotics in Europe. The burden of infections with bacterial resistance to antibiotics on the European population is comparable to that of influenza, tuberculosis and HIV/AIDS combined (Cassini et al., 2019) . It has been estimated that by 2050, 10 million lives a year and a cumulative 100 trillion USD economic output are at risk worldwide due to the rise of drug resistant infections if we do not find proactive solutions to slow down drug resistance (O'Neill, 2016) .
Resistance of Gram-positive bacteria is generally stable or even decreasing in Europe, whereas resistance to Gram-negative bacteria (such as Enterobacterales) has an increasing trend in several European countries (EARS-Net, 2018) .
One of the important resistance mechanisms of Enterobacterales, including Escherichia coli, is the production of extended-spectrum beta-lactamases (ESBLs), AmpC cephalosporinases and carbapenemases. ESBLs include mostly CTX-M, SHV, and TEM enzymes; AmpCs CMY, ACT, and DHA; and carbapenemases KPC, NDM, OXA-48 (Bush and Jacoby, 2010; Bush, 2018) .
Prevalence of these beta-lactamases has been increasing all over the world, including European countries . Data from the European Antimicrobial Resistance Surveillance Network shows that E. coli resistance to thirdgeneration cephalosporins is lower in Northern and higher in the Southern and Eastern Europe (EARS-Net, 2018) . The proportion of invasive E. coli isolates resistant to thirdgeneration cephalosporins by EARS-Net 2017 report was 5.9% in Norway, 8.8% in Estonia, 16.8% in Lithuania, and 22% in Latvia (EARS-Net, 2018) . Comparable data for Russia is absent. Data from WHO CAESAR 2016 report includes a limited number of strains from Western part of Russia and shows high proportion of invasive E. coli isolates resistant to thirdgeneration cephalosporins (66%; World Health Organisation, 2016). However, genes responsible for resistance to the thirdgeneration cephalosporins are not well described in this region (Edelstein et al., 2003; Naseer et al., 2009; Dumpis et al., 2010; Seputiene et al., 2010; Bevan et al., 2017) .
The aim of this study has been to describe the prevalence and molecular mechanisms of resistance to third-generation cephalosporins in E. coli strains isolated from Estonia, Latvia, Lithuania, Norway, and St. Petersburg (Russia) , and to determine the predominant multilocus sequence type and single nucleotide polymorphisms diversity of E. coli isolates deduced by whole genome sequencing (WGS).
MATERIALS AND METHODS

Strain Collection
During a 5 month period in 2012, E. coli clinical isolates from 21 hospitals located in Estonia (n = 5), Latvia (n = 4), Lithuania (n = 3), Norway (n = 1), and St. Petersburg (Russia) (n = 8) were screened for reduced susceptibility to the third-generation of cephalosporins. Briefly, all clinically relevant materials (such as blood, pus, urine, and respiratory tract samples) taken in case of infection from any kind of patients (all ages, outpatients or hospitalized in any department) and sent to microbiology laboratories for culture were included in the study. Surveillance, environmental and clinically irrelevant samples were excluded. All non-duplicate E. coli isolates interpreted as a probable cause of infection were included to the study (excluding clinically irrelevant cases, such as probable colonization or contamination from indigenous microbiota), and tested for third-generation cephalosporins (at least for ceftazidime and ceftriaxone and/or cefotaxime). Duplicates were defined as the same species isolated from the same patients during the study period and showing the same resistance pattern. Thus, the first isolate from a patient was always included. In case of similar isolates that were found from different materials taken at the same time, invasive isolate was preferred (for example, an isolate from blood was collected instead of sputum). Written instructions for sampling and laboratory procedures, and laboratory materials (ESBL/AmpC, confirmations kits, quality control strains, and if needed antibiotic disc) were distributed to all participants. Beforehand our project's country managers and technical coordinators participated in a training course to ensure similar handling of samples, performance of laboratory techniques and quality control.
ESBL/AmpC Screening and Confirmation
Susceptibility testing used disk diffusion according to the guidelines of valid versions at the time of testing of European Committee of Antimicrobial Susceptibility Testing (EUCAST, as in the Baltic countries and Norway) or the Clinical and Laboratory Standards Institute (CLSI, used in St. Petersburg, Russia) . Initial antimicrobial susceptibility testing was performed in each laboratory for local standard panel that includes mandatorily ceftazidime and ceftriaxone and/or cefotaxime. In E. coli isolates with reduced susceptibility to third-generation cephalosporins, ESBL and AmpC cephalosporinases production was confirmed in a local laboratory with a ESBL + AmpC confirmation kit (Rosco Diagnostica, Taastrup, Denmark) provided by the project coordinator. E. coli isolates with the ESBL/AmpC phenotype were stored and sent to Estonian reference center (Human Microbiota Biobank, University of Tartu, Tartu, Estonia) 1 for deposition and future characterization. Identification of all strains was confirmed by MALDI-TOF MS (MALDI Biotyper, Bruker Daltonics GmbH, Germany).
Bacterial DNA Extraction and Whole Genome Sequencing (WGS)
All E. coli isolates with ESBL/AmpC phenotype were sequenced. Briefly, DNA templates for sequencing were generated by growing cultures of E. coli isolates overnight on the Mueller-Hinton agar (Oxoid Limited, United Kingdom). The total bacteria DNA from the strains were extracted using QIAamp DNA Mini Kit (Qiagen, Germany).
Bacterial genomic DNA was quantified using the Qubit R 2.0 Fluorometer (Invitrogen, Grand Island, NE, United States). 1 ng of sample DNA was processed for the sequencing libraries, using Illumina Nextera XT sample preparation kit (Illumina, San Diego, CA, United States). The DNA normalization step was skipped; instead, the final dsDNA libraries were quantified with the Qubit R 2.0 Fluorometer and pooled in equimolar concentrations. The library pool was validated with the 2200 TapeStation (Agilent Technologies, Santa Clara, CA, United States) measurements) and qPCR used the Kapa Library Quantification Kit (Kapa Biosystems, Woburn, MA, United States) to optimize cluster generation. A total of 96 bacterial genomic libraries were sequenced with 2 × 101 bp paired-end (PE) reads on the HiSeq 2500 rapid-run flow cell (Illumina, San Diego, CA, United States). Demultiplexing was done with CASAVA 1.8.2. (Illumina, San Diego, CA, United States), allowing 1 mismatch in index reads.
All sequenced genomes were assembled de novo with assembler Velvet version 1.2 (Zerbino and Birney, 2008) . Before assembly, all reads with low quality were removed after quality control with fastq_quality_trimmer (with parameter values -l 40, -t 30) and fastq_quality_filter (-q 25 -p 90) from FASTX-Toolkit 2 . Velvet was run with different parameter values (-max_gap_count -max_divergence -cov_cutoff -ins_length -min_pair_count) until the best match of E. coli MLST genes was retrieved.
Finding Beta-Lactamase Genes From Assembled Genomes
Beta-lactamase genes were retrieved from the Comprehensive Antibiotic Resistance Database [CARD database; (McArthur et al., 2013) ]. Thereafter, the sequences were searched with BLAST (identity cut-off 90% and alignment length 90% of shortest sequence) from assembled genomes. The assembled contigs were considered to originate from either the plasmid genome or the chromosomal genome based on a BLAST search. We used complete plasmid genomes and complete chromosomal genomes of E. coli from NCBI genomes database for the BLAST search (the best match based on BLAST Score and E-value are used for deciding the origin of a contig).
Multi-Locus Sequence Typing (MLST)
For accurate multi-locus sequence typing of assembled E. coli genomes, a dedicated MLST tool was used, created by Torsten Seemann 3 , that calculates the MLST profile based on a BLAST (Altschul et al., 1997) alignment of the input sequence file and the specified allele set. Public E. coli database (Achtman scheme) for molecular typing was downloaded (with given date: 11.06.2019) from PubMLST 4 . Raw reads from isolates with undetermined MLST types were submitted to Enterobase, which assigned five new sequence types (9656, 9692, 9693, 9694, and 9696) . In order to visualize evolutionary relationships between bacterial strains, we used PHYLOViZ 2.0a (Nascimento et al., 2017 ) that generates complete minimum spanning trees with goeBURST Full MST algorithm.
Core Genome Analysis
Parsnp program from Harvest suite (Treangen et al., 2014) was run to create core genome alignment. The alignment was used to calculate the maximum likelihood phylogenetic tree, with RaxML under GTR-GAMMA model and with 100 bootstrap replicates (Stamatakis, 2014) .
SNP Analysis of ST131 Isolates
ST131 isolates were aligned with Parsnp using Escherichia coli EC958 as a reference ST131 strain (Forde et al., 2014) . Core genome SNPs from the alignment were extracted with harvest-tools and pairwise SNP distances were used for UPGMA tree calculation conducted in MEGA7 (Kumar et al., 2016) . Phylogenetic trees were visualized using iTOL (Letunic and Bork, 2019) .
Statistical Analysis
Statistical analysis used Past 3.22 5 . The prevalence of strains, genes, ST and clones were compared by Chisquared test or Fisher's exact test; p < 0.05 was considered statistically significant.
RESULTS
Phenotypic and Genotypic Epidemiology of ESBL/AmpC/Carbapenemases Producing E. coli Strains
A total of 10,780 consecutive E. coli isolates from Estonia, Latvia, Lithuania, Norway and St. Petersburg (Russia) were screened for reduced sensitivity to third-generation cephalosporins. Of these, 5,486 (51%) were recovered from stationary patients and 5,294 (49%) from outpatients. A total of 508 (4.7%) E. coli strains showed ESBL/AmpC phenotype. Significant inter-country differences were found regarding the prevalence of E. coli showing ESBL/AmpC phenotype (Table 1) . 3, 4, 5, 6, 7, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 From 508 sequenced strains in total, 494 gave accepted sequence quality and could be analyzed. At least one bla (betalactamase) gene (including TEM and SHV other than 2be Bush-Jacoby functional group and bla genes without well characterized function) was found in 468 strains of the 10,780 screened isolates (4.3%, Table 1 ). Of the phenotypic ESBL/AmpC producing strains, 468 out of 494 (94.7%) harbored one of the bla genes: bla CTX−M (n = 383; 77.5%); bla SHV (n = 21; 4%); bla TEM (n = 271; 54.9%); bla CMY (n = 36; 7.9%); bla ACT (n = 3; 0.6%); bla ESC−6 (n = 2; 0.4%); bla FEC−1 (n = 7; 1.4%); bla DHA (n = 12; 2.4%); bla OXA (n = 192; 38.9%); bla NDM (n = 1; 0.2%).
Of 494 resistant strains, 421 (85%) carried any ESBL/AmpC/Carbapenemases encoding genes (Clinic, 2015) . In remaining isolates (n = 74; 15%) no known ESBL/AmpC/Carbapenemases genes were found. Sequencing showed the highest percentage of E. coli strains with the ESBL genotype in St. Petersburg and Latvia compared to Estonia, Norway and Lithuania ( Table 1) .
Prevalence of ESBL (including bla CTX−M , bla TEM−29 , bla TEM−71 ), AmpC (bla CMY−59 , bla ACT−12/−15/−20 , bla ESC−6 , bla FEC−1 , bla DHA−1 ), carbapenemases (bla NDM−1 ) groups and their combinations by countries can be found in Table 2 and Supplementary Figure S1 . In 393 (93%) strains only one ESBL or AmpC was found and in 28 (7%) different genes combinations were detected. The most common combination was bla CTX−M−14 together with bla DHA−1 followed by bla CTX−M−15 with bla CMY−59 ( Table 2) .
Beta-Lactamases Genes
ESBL Genes
In total, 383 out of 468 (81.3%) bla gene-positive E. coli strains had CTX-M gene ( Table 2) . Among ESBL-positive strains, bla CTX−M−15 was predominated (n = 263; 68.7%) followed by bla CTX−M−14 (n = 62; 16.2%). Three isolates had 2 different CTX-M genes (bla CTX−M−15 with bla CTX−M−14 ). In total, 80% of the CTX-M genes were plasmid-mediated and the remaining 20% were located on the chromosome. Chromosome localizations was found in the case of 6 genes: bla CTX−M−1, bla CTX−M−3, bla CTX−M−14, bla CTX−M−15, bla CTX−M−24.
Although, bla CTX−M−15 was the most common gene in all the countries, some inter-country differences were found. This gene was more common in Latvia than in St. Petersburg, Estonia, Norway and Lithuania (82.5 versus 71.8, 61.3, 60.3, and 41.7%; p ≤ 0.01, p ≤ 0.01, p ≤ 0.01; p ≤ 0.001, respectively). Also strains isolated from St. Petersburg had more bla CTX−M−15 genes compared to Lithuanian strains (71.8 vs. 41.7%; p < 0.05). Lithuanian strains carried more bla CTX−M−14 genes than Latvian strains (33.3 vs. 5.6%; p = 0.0005).
ESBL associated TEM genes were found only in 2 cases: bla TEM−29 in Estonian and bla TEM−71 in Lithuanian.
AmpC Genes
Out of 468 E. coli strains with any bla gene, 60 (12.8%) were harboring one of the AmpC type gene. All bla ACT−12/−15/−20, bla DHA−1 , bla FEC−1 genes were located in plasmid, bla ESC−6 in chromosome and bla CMY−59 in plasmid or chromosome. The most prevalent AmpC-like genes were bla CMY−59 (n = 36; 60%), bla DHA−1 (n = 12; 20%), and bla FEC−1 (n = 7; 11.7%) alone or in combination with other genes ( Table 2) .
Other Beta-Lactamase Genes
A total of 271 (57.9%) E. coli strains with any bla gene carried bla TEM : bla TEM−1 , bla TEM−29 , bla TEM−71 , bla TEM−76 , bla TEM−98 , bla TEM−135 , bla TEM−150 , bla TEM−198 ,and bla TEM−199. The most dominant strain was bla TEM−1 (in 246 strains). Only, 21 (4.5%) bla gene-positive E. coli strains had bla SHV−188 gene; however, the activity of SHV-188 enzyme has not been properly described. 192 (41%) bla gene-positive E. coli strains carried bla OXA−1 and 1 strain bla OXA−7. However, enzymes coded by these genes are not real ESBLs. One carbapenemase plasmid-associated bla NDM−1 gene was found in combination with bla CMY−59 ( Table 2) .
Genotypes of Bla Genes Containing E. coli Strains
We identified 83 different sequence types, the most prevalent being ST131 (n = 198; 40%), followed by ST38 (n = 37; 7.5%), ST405 (n = 32; 6.5%), ST167 (n = 19; 3.8%), and ST2015 (n = 18; 3.6%). The prevalence of other sequence types was <3%. When ST131 was common in all the countries, then ST167 was mainly found in Latvia (14/19; 73.7%), ST38 (25/37; 67.6%), and ST405 (27/32; 84.4%) in St. Petersburg and ST2015 (18/18; 100%) was found only in Estonia. Four sequence types were found in all countries: ST69, ST131, ST354, and ST405 (Figure 1 and  Supplementary Figure S2) .
ST131 was most common in Latvia (63/109; 57.8%), followed by Estonia (61/147; 41.5%), Lithuania (11/34; 32.4%), St. Petersburg (43/135; 31.9%) , and Norway (20/6; 29%). In Latvia, the proportion of ST131 among ESBL strains was significantly higher than in St. Petersburg and Norway (p ≤ 0.001, p ≤ 0.001, respectively). Estonian strains belonged to more different sequence type groups when compared to Latvia, Lithuania and Norway (43 vs. 26, 19, 26 ; p ≤ 0.01, p ≤ 0.001, p ≤ 0.01, respectively). In St. Petersburg there were 30 different sequence types.
In ST131 strains, 7 different CTX-M genes were found: Analysis of single nucleotide polymorphisms (SNPs) in shared genome blocks revealed 18,888 SNPs present in the core genome of ST131 strains. Differences compared to reference EC958 ranged from 17 to 7,067 SNPs (Supplementary Figure S3) . Four groups were detected among ST131 strains containing isolates from different countries, and having in-group average pairwise SNP distances of<20 (n = 40 strains; Supplementary  Figure S4 ). SNP differences inside those four groups were 0-8.8 SNPs/Mbp of the ST131 core genome (∼3.4 Mbp). The average amount of SNPs between the groups was less than 110. One such group was also very close to reference EC958 strain. SNP tree of all E. coli strains is given in Supplementary Figure S2 .
DISCUSSION
This study describes the phenotypic and molecular epidemiology of E. coli strains with reduced susceptibility to third-generation cephalosporins in Northern and Eastern Europe by screening of more than 10,000 E. coli strains. The overall prevalence of ESBL/AmpC strains was 4.7% by phenotypical test and 3.9% by sequencing. We found more strains with the ESBL/AmpC phenotype and genotype in St. Petersburg and Latvia than in other countries. According to our knowledge this is the first study analyzing beta-lactamases epidemiology of E. coli using WGS and describing in detail resistance genes, distribution of MLST and SNP clones in this region.
Although several reports have been previously published, scope, methodology and data quality in these studies vary. Edelstein's group investigated E. coli strains from Russia, and found that the prevalence of phenotypic ESBL-positive strains was close to 16%; however, prevalence figures in different institutions varied from 10 to 90% (Edelstein et al., 2003) .
WHO CAESAR study reports high prevalence (66%) of thirdgeneration cephalosporins resistance in invasive E. coli strains in Russia, however the number of strains was small (World Health Organisation, 2016) . This high variance might be dependent upon different antibiotic use policies in different Russian regions and hospitals. Our results also showed a relatively high prevalence of ESBL/AmpC phenotype in St. Petersburg area compared to other countries. However, it is impossible to draw final conclusions about the overall prevalence of ESBL/AmpC/Carbapenemases in Russia at large, since the strains were collected only from St. Petersburg region, and thus reflects the situation in only one city.
In a previous Eastern European study conducted between 2004-2010 that included 42 centers, the average ESBL phenotype prevalence among E. coli strains was 15.3%, with the highest prevalence in South-East European countries -Turkey (25.2%), Bulgaria (15.7%) and Romania (12.2%) -and lowest in Central and North-East European countries -Croatia (3.6%) Czechia (3.6%), Latvia (3.6%), Slovenia (2.7%), and Lithuania (1.8%) (Balode et al., 2013) . In a similar following study done between 2011 and 2016, the E. coli ESBL phenotype average prevalence was higher when compared to the previous survey (20.1 vs. 15.3%) (Balode et al., 2013; Dowzicky and Chmelarova, 2018) . However, in these studies, phenotypic tests detecting only ESBL (not AmpC) were used. In countries of Western and Northern Europe, a prevalence of ESBL producing bacteria was low in the Netherlands (6.1%), Germany (7.7%), Sweden (2-4%), and Norway (1.5%) Soraas et al., 2014; Zhou et al., 2017) .
When comparing ESBL/AmpC prevalence in different studies several aspects should be taken into account. Different methods and criteria have been used in different studies such as decreased sensitivity to third-generation cephalosporins as an indicator of ESBL; phenotypic confirmation test for ESBL alone or ESBL combined with AmpC. In studies where molecular methods were applied, different approaches have been used: searching only for CTX-M types or including also TEM, SHV and AmpC type genes.
Besides differences in detection methodologies several other factors might influence the results and potential cause over as well as underestimation of ESBL/AmpC prevalence and resistance percentages. One such factor is the use of different sampling practices in different institutions noted also by EARS-Net as a factor that should be taken into account in interpreting intercountry differences (EARS-Net, 2018) . A similar limitation is present in all studies using clinical strains from routine cultures, including our study.
We found more strains with ESBL/AmpC phenotype than strains with known ESBL/AmpC gene. Several reasons can cause this: other mechanisms such as possible hyperproducers of intrinsic (chromosomal) cephalosporinase combined or not with alteration in porin channels can lead to resistance to thirdgeneration cephalosporins; bla genes databases are not complete -we probably don't know all ESBL/AmpC genes or not all are submitted to databases, furthermore these genes are changing and new variants may not be recognized; we found in our strains several genes (such as SHV and TEM variants) without information about their belonging to particular Bush-Jacoby functional group (ESBL/AmpC or not). Only well described ESBL/AmpC genes were included in this study.
The most common ESBL genes in our study were bla CTX−M−15 and bla CTX−M−14 . These enzymes have been reported throughout Asia, Africa, Europe, America and Australia (Livermore et al., 2007; Sidjabat et al., 2010; Iroha et al., 2012; Chen et al., 2014; Pietsch et al., 2017) . So far, the CTX-M-15 genotype appears to be the most prevalent in all continents, and our findings are in accordance with previous reports Canton et al., 2012; Iroha et al., 2012; Voets et al., 2012; Brolund et al., 2014; Chen et al., 2014;  In general, prevalence of ESBL, AmpC and Carbapenemases genes was low in investigated E. coli strains. However, several inter-country differences notably in distribution of particular genes, MLST groups and SNP clones, were described.
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